Hematologic Oncology

The FDA has granted fast track designation to gamgertamig for autoimmune hemolytic anemia and immune thrombocytopenia.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.

FDA announces new CRL for tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Tsewang Tashi, MD, expands on long-term bone health data with avapritinib in patients with indolent systemic mastocytosis from the PIONEER trial.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tafasitamab/lenalidomide added to first-line R-CHOP improved PFS vs R-CHOP alone with no new safety signals in patients with DLBCL.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

The FDA has received a new drug application seeking the approval of bezuclastinib for the treatment of patients with non-advanced systemic mastocytosis.

Lodovico Balducci, MD, built a new discipline from the ground up, which kick-started pivotal research in geriatric oncology.

NXC-201 demonstrated organ responses in 70% of evaluable patients with relapsed/refractory light chain amyloidosis.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

Franco Cavalli, MD, has dedicated his life to treating patients, developing drugs, and bringing higher quality cancer care to areas in need of improvement

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

The FDA has granted accelerated approval to subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma after 2 prior therapies.